The new heart failure guidelines: Strategies for implementation

American Heart Journal

Volumn 153, Issue 4 SUPPL., 2007, Pages 2-5

  O'Connor, Christopher M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART FAILURE; HUMAN; LOW DRUG DOSE; MORBIDITY; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL;

EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; PRACTICE GUIDELINES;

EID: 33947544855     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.01.010     Document Type: Article

References (26)

1. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Rich M.W. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 45 (1997) 968-974
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
4. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327 (1992) 685-691
5. The IMPACT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
6. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325 (1991) 303-310
7. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
8. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344 (2001) 1651-1658
9. Pfeffer M.A., Swedberg K., Granger C.B., et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
10. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
11. Pitt B., Remme W.J., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1320
12. Abraham W.T., Fisher W.G., Smith A.L., et al. Cardiac resynchronization in chronic heart failure. N Engl J Med 346 (2002) 1845-1853
13. Bardy G.H., Lee K.L., Mark D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 (2005) 225-237
14. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology Web Site. Available at: http://www.acc.org/clinical/guidelines/failure/index.pdf. Circulation 112 (2005) 1825-1852
15. Lee D.S., Mamdani M.M., Austin P.C., et al. Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000. Am J Med 116 (2004) 581-589
16. Bertoni A.G., Duren-Winfield V., Ambrosius W.T., et al. Quality of heart failure care in managed Medicare and Medicaid patients in North Carolina. Am J Cardiol 93 (2004) 714-718
17. Fonarow G.C., Yancy C.W., and Heywood J.T. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med 165 (2005) 1469-1477
18. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005) 209-216
19. Fonarow G.C., Gawlinski A., Moughrabi S., et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-822
20. Ohman E.M., Roe M.T., Smith Jr. S.C., et al. Care of non-ST-segment elevation patients: insights from the CRUSADE national quality improvement initiative. Am Heart J 148 (2004) S34-S39
21. Lappe J.M., Muhlestein J.B., Lappe D.L., et al. Improvements in 1-year cardiovascular clinical outcomes associated with a hospital-based discharge medication program. Ann Intern Med 141 (2004) 446-453
22. Gheorghiade M., Gattis W.A., Lukas M.A., et al. Rationale and design of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) study. Am Heart J 145 (2003) S60-S61
23. Gattis W.A., O'Connor C.M., Gallup D.S., et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. J Am Coll Cardiol 43 (2004) 1534-1541
24. O'Connor C.M., Stough W.G., Gallup D.S., et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 11 (2005) 200-205
25. Fonarow G.C., Abraham W.T., Albert N.M., et al. Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 148 (2004) 43-51
26. Fonarow G.C., Abraham W.T., Albert N.M., et al. Impact of evidence-based heart failure therapy use at hospital discharge on treatment rates during follow-up: a report from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF) [abstract]. J Am Coll Cardiol 45 (2005) 345A [Abstract 4]